← Leaderboards
Andrew P Escayg
Emory University
$12,950,611
Attributed
$15,993,795
Total exposure
19
Grants
18
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$15,993,795 · 19
By mechanism
R01$12,295,398 · 9
R21$3,396,315 · 8
R03$302,082 · 2
Top collaborators
- Alan L Goldin8 shared
- Kevin Sean Murnane7 shared
- Martin J. D'Souza1 shared
Most similar at Emory University
Same institution · by research overlap
- Kevin Sean Murnane$3,602,168
- Christopher Donald Makinson$4,071,363
- George Andrew Stanowski Inglis$82,602
- Douglas C Wallace$28,541,550
- Jennifer C. Wong$736,230
Others in their field
Top investigators on “Epilepsy”
- Karen Wilcox · University Of Utah$40,784,208
- Mark J Daly · Broad Institute, Inc.$39,233,325
- Wayne N. Frankel · Jackson Laboratory$37,394,025
- Shlomo Shinnar · Montefiore Medical Center (Bronx, Ny)$34,999,274
- Christopher A Walsh · Beth Israel Deaconess Medical Center$34,874,606
- Stacey Gabriel · Massachusetts Institute Of Technology$34,637,180
Research focus
EpilepsySeizuresMouse ModelNeuronsMutationResistanceSodium ChannelVoltageMutantGenesFebrile ConvulsionsPhenotypeNeuronal ExcitabilityBrainBasePlayClinically RelevantGenerationsFunctional DisorderLeadBehavioralNervous System DisorderExhibitsHippocampus (Brain)
Grant awards (48)
SCN8A encephalopathy: disease mechanisms and treatment$470,230
R01 · FY2025 · NS · contact PI
Exploring the role of oxytocin in the regulation of neuronal excitability$470,143
R01 · FY2025 · NS · contact PI
SCN8A encephalopathy: disease mechanisms and treatment$506,144
R01 · FY2024 · NS · contact PI
Exploring the role of oxytocin in the regulation of neuronal excitability$457,373
R01 · FY2024 · NS · contact PI
SCN8A encephalopathy: disease mechanisms and treatment$553,774
R01 · FY2023 · NS · contact PI
Exploring the role of oxytocin in the regulation of neuronal excitability$472,869
R01 · FY2023 · NS · contact PI
Exploring the role of oxytocin in the regulation of neuronal excitability$474,192
R01 · FY2022 · NS · contact PI
Exploring the role of GADD45A in Alzheimer's disease$416,071
R21 · FY2022 · AG · contact PI
Exploring the role of oxytocin in the regulation of neuronal excitability$517,488
R01 · FY2021 · NS · contact PI
N-terminal huntingtin and Huntington disease neuropathology$448,409
R01 · FY2021 · NS · contact PI
Neuronal function of huntingtin-associated protein$396,395
R01 · FY2021 · NS · contact PI
Altering the development of epilepsy through CB2R activation$416,112
R21 · FY2020 · NS · contact PI
Neuronal function of huntingtin-associated protein$396,395
R01 · FY2020 · NS · contact PI
Exploring the range of seizure and behavioral phenotypes due to SCN8A mutations$150,673
R03 · FY2020 · NS · contact PI
Exploring reversible AChE inhibitors as a treatment for refractory epilepsies$425,449
R21 · FY2019 · NS · contact PI
Neuronal function of huntingtin-associated protein$396,395
R01 · FY2019 · NS · contact PI
Towards a better understanding of the regulation of the SCN1A sodium channel$189,927
R21 · FY2019 · NS · contact PI
A novel target for the treatment of temporal lobe epilepsy$466,679
R01 · FY2018 · NS · contact PI
Towards a better understanding of the regulation of the SCN1A sodium channel$229,388
R21 · FY2018 · NS · contact PI
A novel target for the treatment of temporal lobe epilepsy$466,344
R01 · FY2017 · NS · contact PI
A novel neuropeptide brain delivery system for epilepsy$193,888
R21 · FY2017 · NS
Towards the development of an effective treatment for SCN1A-derived epilepsy$193,486
R21 · FY2017 · NS · contact PI
A novel target for the treatment of temporal lobe epilepsy$465,815
R01 · FY2016 · NS · contact PI
A novel neuropeptide brain delivery system for epilepsy$246,220
R21 · FY2016 · NS
Towards the development of an effective treatment for SCN1A-derived epilepsy$232,624
R21 · FY2016 · NS · contact PI
A novel target for the treatment of temporal lobe epilepsy$479,441
R01 · FY2015 · NS · contact PI
SCN1A dysfunction and neuropsychiatric comorbidities$193,950
R21 · FY2015 · NS · contact PI
Understanding the role of sodium channels in epilepsy$322,458
R01 · FY2014 · NS · contact PI
SCN1A dysfunction and neuropsychiatric comorbidities$232,950
R21 · FY2014 · NS · contact PI
Understanding the role of sodium channels in epilepsy$315,422
R01 · FY2013 · NS · contact PI
Understanding the role of sodium channels in epilepsy$327,866
R01 · FY2012 · NS · contact PI
Scn8a and Seizure Resistance$315,701
R01 · FY2012 · NS · contact PI
Understanding the role of sodium channels in epilepsy$342,498
R01 · FY2011 · NS · contact PI
Scn8a and Seizure Resistance$317,474
R01 · FY2011 · NS · contact PI
A mouse model of human idiopathic generalized epilepsy$74,940
R03 · FY2011 · NS · contact PI
Scn8a and Seizure Resistance$322,284
R01 · FY2010 · NS · contact PI
Towards the development of a novel treatment for epilepsy$193,750
R21 · FY2010 · NS · contact PI
A mouse model of human idiopathic generalized epilepsy$76,469
R03 · FY2010 · NS · contact PI
Scn8a and Seizure Resistance$338,383
R01 · FY2009 · NS · contact PI
Towards the development of a novel treatment for epilepsy$232,500
R21 · FY2009 · NS · contact PI
SODIUM CHANNEL REGULATION AND DISEASE$268,383
R01 · FY2008 · NS · contact PI
Sodium Channel Dysfunction and Epilepsy$268,383
R01 · FY2008 · NS · contact PI
SODIUM CHANNEL REGULATION AND DISEASE$268,383
R01 · FY2007 · NS · contact PI
Sodium Channel Dysfunction and Epilepsy$268,383
R01 · FY2007 · NS · contact PI
SODIUM CHANNEL REGULATION AND DISEASE$276,399
R01 · FY2006 · NS · contact PI
Sodium Channel Dysfunction and Epilepsy$276,399
R01 · FY2006 · NS · contact PI
Sodium Channel Dysfunction and Epilepsy$345,846
R01 · FY2005 · NS
SODIUM CHANNEL REGULATION AND DISEASE$283,050
R01 · FY2005 · NS